The closest structural homologue of BLyS (33% protein sequence identity) is the TNF family member APRIL [9] .
Given this similarity, we tested whether APRIL interacts with BCMA or TACI (Figure 1b ). Like BLyS, soluble FLAG-tagged APRIL bound to BCMA-Fc and to TACI-Fc . In contrast to a recent report [14] , we did not observe binding of FLAG-APRIL to Fas-Fc or HVEM-Fc ( Figure 1b) . Immunoprecipitation of each ligand through the FLAG tag followed by immunodetection of bound receptor through the Fc tag revealed identical interactions (data not shown).
Most TNF family members, including BLyS and APRIL, are expressed as type 2 transmembrane proteins. To test whether the transmembrane forms of these two ligands recognize BCMA and TACI, we transfected COS7 cells with expression vectors carrying each full-length ligand's cDNA, and stained the cells with receptor-Fc fusion proteins. BCMA-Fc and TACI-Fc bound to cells transfected Interaction of BLyS and APRIL with BCMA and TACI. Purified BCMA-Fc, TACI-Fc, Fas-Fc, or HVEM-Fc (1 mg/ml) was incubated with purified FLAG-BLyS, FLAG-APRIL, FLAG-FasL, or FLAG-LIGHT (1 mg/ml) as indicated for 1 h at 24°C. The reactions were subjected to immunoprecipitation (IP) through the receptor-Fc fusion with protein-A-agarose and analyzed by western blot (WB) with an anti-FLAG antibody M2 (Sigma) to detect the bound ligands. FLAG-BLyS FLAG-APRIL FLAG-FasL FLAG-LIGHT
with transmembrane BLyS or APRIL but not to cells transfected with full-length TNF, whereas TNFR1-Fc bound to cells transfected with TNF, but not to BLyS-or APRIL-transfected cells (Figure 2a-i ).
Unlike the majority of known TNFR family members [15] , but similar to TACI [5] , BCMA does not contain a typical amino-terminal signal sequence, suggesting that it may be a type 3 rather than a type 1 transmembrane protein. Previous work suggested that BCMA is located in the Golgi compartment [16] . If BCMA and TACI are expressed at the cell surface, then they should be recog- binding of BLyS or APRIL to BCMA or TACI occurs at apparently physiological concentrations.
The signaling mechanisms of BCMA have not been characterized. Therefore, we investigated whether BCMA activates NF-kB in response to BLyS (Figure 4a,b) . In addition, we tested APRIL's ability to stimulate NF-kB through BCMA or TACI. Treatment of 293 cells transfected with expression vectors encoding native sequence, full-length BCMA or TACI with purified soluble FLAGtagged BLyS or APRIL induced marked NF-kB activation relative to controls, as measured by a reporter-gene assay ( Figure 4a ). Next, we examined whether co-transfection of 293 cells with expression plasmids encoding each fulllength ligand and receptor combination leads to NF-kB stimulation (Figure 4b ). BLyS and APRIL induced significant NF-kB activation through BCMA and TACI. Thus, both BLyS and APRIL can stimulate NF-kB through either BCMA or TACI. TACI has been reported to activate the T cell transcription factor NF-AT [5] . Because BCMA and TACI activated NF-kB despite the lack of clear sequence homology in their cytoplasmic region, it is formally possible that BCMA can activate NF-AT as well. Our results demonstrate that BLyS is not the sole ligand of TACI and BCMA; rather, the closest relative of BLyS in the TNF gene family, APRIL, interacts with these same receptors. APRIL has been reported to stimulate the growth of various tumor cell lines [9] ; however, its physiological role is not fully understood. Whether TACI, BCMA, or some other receptor(s) mediate APRILinduced proliferation is yet to be investigated.
BLyS is implicated in B-cell activation and it stimulates immunoglobulin production by B cells [1-4,17]. We investigated whether APRIL modulates B cells as well by testing B cell
In previous work, we identified TACI as a B-cell receptor for BLyS by expression cloning [6] . Treatment of mice with a TACI-Fc fusion protein after antigenic challenge diminished IgM and IgG production and abolished splenic germinal center formation. These data suggested that the interactions of BLyS and TACI are crucial for humoral immunity. During review of this manuscript, Gross et al. [18] reported that TACI and BCMA are receptors for BLyS and showed that treatment with TACI-Fc ameliorated disease and improved survival in mouse models of systemic lupus erythematosus (SLE), a B-cell-mediated autoimmune disease. Taken together, these findings suggest that TACI-Fc exerts its therapeutic effect on mouse SLE by perturbing the generation of Brief Communication 787
Figure 4
Activation of NF-kB and of IgM production by BLyS and APRIL. autoantibodies. Although these effects of TACI-Fc were previously ascribed to inhibition of BLyS [6, 18] , this study, which uncovers APRIL as a second ligand for TACI, suggests that APRIL inhibition also may contribute to the effects of TACI-Fc on immunization and SLE. In addition, it is likely that TACI-Fc blocks the interactions of BLyS and APRIL not only with cellular TACI, but also with BCMA, which is expressed in lymphoid organs and B lymphocytes [19] . Thus, BLyS and APRIL and their receptors TACI and BCMA may act in concert to regulate B-cell function. Further studies, particularly gene knockout experiments, should help define more fully the individual contribution of each member of this newly defined ligand-receptor system to humoral immunity in health and disease.
Materials and methods
Fc fusion proteins (immunoadhesins) were constructed using amino acids 5-51 of human BCMA [7, 8] , 2-166 of human TACI [5] , 1-170 of Fas [10] , or 1-199 of HVEM [11] , and expressed in Chinese hamster ovary (CHO) cells using a heterologous signal sequence (prepro-trypsin amino acids 1-17) for BCMA and TACI, or the endogenous signal sequence for Fas and HVEM. FLAG-tagged ligands were constructed in pCMV-1 Flag (Sigma) using amino acids 124-285 of human BLyS [1] , 105-250 of human APRIL [9] , 103-251 of human FasL, and 82-240 of human LIGHT [13] . Ligands were expressed in CHO cells and purified by affinity chromatography on anti-Flag M2-agarose (Sigma).
AP fusion proteins were constructed by inserting the human AP coding sequence derived from pAPtag-5 (Genehunter Corp.) into each pCMV-1 FLAG-ligand vector between the Flag tag and the ligand sequences.
The total amount of transfected DNA in co-transfection experiments was kept constant at 1 mg by supplementation with empty vector.
